NCT00780403View on ClinicalTrials.gov

Multi-Center, Pediatric, Open-Label, Preference Study of Desloratadine 2.5 mg Reditab (SCH34117) and Zyrtec ® 5.0 mg Chewable Tablet Medications (Study P04573) (Completed)

PHASE4CompletedINTERVENTIONAL

Enrollment

220

Participants

Timeline

Start Date

August 31, 2005

Primary Completion Date

October 31, 2005

Study Completion Date

October 31, 2005

Conditions

Allergies

Interventions

DRUG

Desloratadine

desloratadine RediTabs, 1 tablet (2.5 mg),oral administration, single day

DRUG

Zyrtec® (cetirizine)

Zyrtec® (cetirizine) Chewable Tablets, 1 tablet (5 mg), oral administration, single day

All Listed Sponsors

lead

Organon and Co

INDUSTRY

NCT00780403 - Multi-Center, Pediatric, Open-Label, Preference Study of Desloratadine 2.5 mg Reditab (SCH34117) and Zyrtec ® 5.0 mg Chewable Tablet Medications (Study P04573) (Completed) | Biotech Hunter | Biotech Hunter